EZZ Life Science Holdings Inkomsten in het verleden
Verleden criteriumcontroles 5/6
EZZ Life Science Holdings has been growing earnings at an average annual rate of 32.7%, while the Life Sciences industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 31.2% per year. EZZ Life Science Holdings's return on equity is 32.7%, and it has net margins of 10.5%.
Belangrijke informatie
32.7%
Groei van de winst
24.7%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 19.7% |
| Inkomstengroei | 31.2% |
| Rendement op eigen vermogen | 32.7% |
| Nettomarge | 10.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
EZZ Life Science Holdings Limited (ASX:EZZ) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Nov 04
EZZ Life Science Holdings Limited's (ASX:EZZ) Shares Leap 41% Yet They're Still Not Telling The Full Story
Aug 28EZZ Life Science Holdings Limited (ASX:EZZ) Stock Catapults 29% Though Its Price And Business Still Lag The Market
Jun 05There's No Escaping EZZ Life Science Holdings Limited's (ASX:EZZ) Muted Earnings Despite A 28% Share Price Rise
Apr 02Here's Why We Think EZZ Life Science Holdings (ASX:EZZ) Is Well Worth Watching
Feb 09EZZ Life Science Holdings Limited's (ASX:EZZ) Share Price Is Matching Sentiment Around Its Earnings
Oct 18EZZ Life Science Holdings' (ASX:EZZ) Promising Earnings May Rest On Soft Foundations
Mar 06Calculating The Fair Value Of EZZ Life Science Holdings Limited (ASX:EZZ)
Nov 22Opbrengsten en kosten
Hoe EZZ Life Science Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 66 | 7 | 38 | 0 |
| 31 Mar 24 | 55 | 5 | 32 | 0 |
| 31 Dec 23 | 44 | 3 | 26 | 0 |
| 30 Sep 23 | 40 | 4 | 24 | 0 |
| 30 Jun 23 | 37 | 4 | 22 | 0 |
| 31 Mar 23 | 31 | 3 | 16 | 0 |
| 31 Dec 22 | 24 | 3 | 11 | 0 |
| 30 Sep 22 | 19 | 2 | 7 | 0 |
| 30 Jun 22 | 15 | 1 | 4 | 0 |
| 31 Mar 22 | 15 | 1 | 5 | 0 |
| 31 Dec 21 | 16 | 1 | 5 | 0 |
| 30 Sep 21 | 19 | 1 | 7 | 0 |
| 30 Jun 21 | 22 | 2 | 9 | 0 |
| 31 Mar 21 | 22 | 2 | 7 | 0 |
| 31 Dec 20 | 21 | 2 | 6 | 0 |
| 30 Sep 20 | 20 | 2 | 4 | 0 |
| 30 Jun 20 | 18 | 2 | 2 | 0 |
| 30 Jun 19 | 11 | 1 | 3 | 0 |
Kwaliteitswinsten: EZZ has a high level of non-cash earnings.
Groeiende winstmarge: EZZ's current net profit margins (10.5%) are higher than last year (9.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: EZZ's earnings have grown significantly by 32.7% per year over the past 5 years.
Versnelling van de groei: EZZ's earnings growth over the past year (91.9%) exceeds its 5-year average (32.7% per year).
Winst versus industrie: EZZ earnings growth over the past year (91.9%) exceeded the Life Sciences industry -5.7%.
Rendement op eigen vermogen
Hoge ROE: EZZ's Return on Equity (32.7%) is considered high.